Calliditas Therapeutics AB (publ)
CALT
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 49.16% | -31.92% | -402.62% | -1,701.91% | 55.38% |
| Total Depreciation and Amortization | -- | -- | 29.45% | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 433.00% | 93.80% | 22.20% | 245.71% | -72.25% |
| Change in Net Operating Assets | 35.64% | 122.01% | -115.98% | 168.98% | -119.09% |
| Cash from Operations | 95.75% | 14.12% | -90.00% | 51.11% | 32.39% |
| Capital Expenditure | -- | -- | -412.88% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 90.57% | -33.09% | 904.40% | -714.23% | -614.18% |
| Cash from Investing | 90.57% | -33.09% | -61.72% | -714.23% | -614.18% |
| Total Debt Issued | -- | -- | 277.18% | -- | -- |
| Total Debt Repaid | -34.66% | -84.14% | -25,336.60% | -12.42% | -19.31% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -2,009.83% | -- | -- |
| Cash from Financing | -32.08% | -85.08% | -25.68% | -9.64% | -101.19% |
| Foreign Exchange rate Adjustments | -109.24% | 1,804.85% | -2,552.26% | -135.93% | 68.74% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -200.00% | -- | -- |
| Net Change in Cash | 91.29% | 30.26% | -63.30% | 30.11% | -743.69% |
